International Osteoporosis Foundation Announces First-of-its-Kind Partnership With University of Oxford, Amgen and UCB to Combat Global Public Health Burden of Osteoporosis1
Hip and Vertebral Fractures are Costly for Society and Can be Life-Altering for Patients2,3
NYON, Switzerland (June 16, 2020) — Amgen (NASDAQ: AMGN) and UCB (Euronext Brussels: UCB) today announced a collaboration with the International Osteoporosis Foundation (IOF) to support its Capture the Fracture® program to reduce hip and vertebral fractures by 25% by 2025. Currently, it is estimated that more than 200 million people worldwide suffer from osteoporosis,4 resulting in an osteoporosis-related fracture every three seconds.5
Osteoporosis is a serious chronic condition that weakens bones over time, making them thinner and more likely to break,5 but there are steps patients and healthcare providers can take to reduce fracture risk.1 Capture the Fracture, an IOF initiative, now supported by Amgen and UCB in collaboration with the University of Oxford, is a global program that helps to proactively implement post-fracture care (PFC) coordination programs in hospitals and healthcare systems to help patients prevent subsequent fractures due to osteoporosis. Even after an osteoporosis-related fracture approximately 80% of individuals at high risk are still not identified or treated.6
“Osteoporosis remains a global concern, resulting in 8.9 million fractures in a single year3 and a previous fracture increases the risk of another osteoporosis-related fracture by 86%.7Early intervention through improved post-fracture identification, diagnosis and treatment in appropriate patients can help improve outcomes while also lessening the cost burden on healthcare systems,”5 said Darryl Sleep, M.D., senior vice president of Global Medical and chief medical officer at Amgen. “Supporting Capture the Fracture represents our proactive approach to care designed to predict and help prevent potentially life-altering fractures before they happen.”
“We are currently witnessing a significant disease burden. As the worldwide aging population steadily increases, it has never been more important to address the impact that osteoporosis and associated fractures can have on individuals,” said professor Cyrus Cooper, president of the International Osteoporosis Foundation and professor of Musculoskeletal Science at the University of Oxford.
“We know post-fracture coordinated care implementation is the most effective8 and efficient intervention to close the secondary fracture prevention gap, so I’m delighted that Amgen, UCB and the University of Oxford will support our Capture the Fracture program as we embark on a mission to improve outcomes for patients,” said IOF chief executive officer, Dr. Philippe Halbout.
Osteoporosis is treated by multiple specialties, underscoring the need for coordinated care to support patients with the disease. At the core of the Capture the Fracture model is a care coordinator who can help patients with an osteoporosis-related fracture be identified, screened, diagnosed and appropriately treated to reduce their future fracture risk. Post-fracture care coordination programs have been shown to improve diagnosis and treatment rates.8,9 This partnership aims to double the 390 existing Capture the Fracture programs by the end of 2022, and will focus on key regions including Asia Pacific, Latin America, the Middle East, and Europe.
“The introduction of the post-fracture care model is recognized as a progressive milestone in the management of osteoporosis and osteoporotic fractures, and remains a profound example of what good looks like in coordination of care among multiple disconnected players,” said Professor Dr. Iris Loew-Friedrich, chief medical officer and executive vice president, UCB. “Collaboration and cross learning are necessary if we are to face the challenges of the future and find a way to lessen the burden faced by healthcare systems and people living with osteoporosis. This global partnership supports UCB's ambition of connected healthcare, finding ways to deliver more for the patient and transforming the lives of people with severe diseases.”
This partnership also welcomes collaboration from existing fracture prevention coalitions on international, national and regional levels to drive fracture prevention policy change and prioritization. Additional elements of the partnership include developing and implementing efficiencies and best practice sharing across PFC program sites, creating a digital tool that documents and communicates PFC effectiveness, and providing virtual and in-person mentorship and learning opportunities for healthcare providers.
“Capture the Fracture is an incredible opportunity to take the academic skills and expertise from the University to deliver real improvements in patient care for osteoporosis,” said Dr. Kassim Javaid, associate professor, the Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS), University of Oxford. Dr. Javaid, along with Dr. Rafael Pinedo-Villanueva, will be responsible for the mentorship program and for developing care pathway and benefits calculator software for the PFC program. “We hope that through this program millions of lives will be changed and we look forward to working with national and international colleagues to deliver this vision.”
For more information about Capture the Fracture, please visit http://www.capturethefracture.org.
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
About International Osteoporosis Foundation
The International Osteoporosis Foundation (IOF) is a registered not-for-profit, non-governmental foundation based in Switzerland. IOF has been granted Roster Consultative Status with the Economic and Social Council of the United Nations.
IOF functions as a global alliance of patient societies, research organizations, healthcare professionals and international companies working to promote bone health and prevent fractures due to osteoporosis. www.iofbonehealth.org
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With 7 500 people in approximately 40 countries, the company generated revenue of € 4.9 billion in 2019. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news
About University of Oxford
Oxford University has been placed number 1 in the Times Higher Education World University Rankings for the fourth year running, and at the heart of this success is our groundbreaking research and innovation.
Oxford is world-famous for research excellence and home to some of the most talented people from across the globe. Our work helps the lives of millions, solving real-world problems through a huge network of partnerships and collaborations. The breadth and interdisciplinary nature of our research sparks imaginative and inventive insights and solutions.
About The Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS)
The Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS) is a multi-disciplinary department focusing on discovering the causes of musculoskeletal and inflammatory conditions to deliver excellent and innovative care that improves people’s quality of life. The largest European academic department in its field, NDORMS is part of the Medical Sciences Division of the University of Oxford and is a rapidly growing community of more than 500 orthopaedic surgeons, rheumatologists and scientists all working in the field of musculoskeletal disorders.
The research work of the department takes place in several locations across the Nuffield Orthopaedic Centre, namely the Botnar Research Centre, the Kennedy Institute of Rheumatology, and the Kadoorie Centre. The co-location with NHS services puts the department in an excellent position with basic researchers working alongside clinicians. This substantially improves research capacity, improving access for researchers to patients, and facilitating the interaction between clinicians and scientists that is essential for successful medical research. www.ndorms.ox.ac.uk
Amgen Forward-Looking Statements
This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company, including Adaptive Biotechnologies (including statements regarding such collaboration’s ability to discover and develop fully-human neutralizing antibodies targeting SARS-CoV-2 to potentially prevent or treat COVID-19), BeiGene, Ltd., or the Otezla® (apremilast) acquisition, including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion, as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems such as the ongoing COVID-19 pandemic on Amgen’s business, outcomes, progress, or effects relating to studies of Otezla as a potential treatment for COVID-19, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including its most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.
No forward-looking statement can be guaranteed and actual results may differ materially from those Amgen projects. Amgen’s results may be affected by its ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing its products and global economic conditions. In addition, sales of Amgen’s products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, Amgen’s research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Amgen or others could identify safety, side effects or manufacturing problems with its products, including its devices, after they are on the market. Amgen’s business may be impacted by government investigations, litigation and product liability claims. In addition, Amgen’s business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If Amgen fails to meet the compliance obligations in the corporate integrity agreement between Amgen and the U.S. government, Amgen could become subject to significant sanctions. Further, while Amgen routinely obtains patents for its products and technology, the protection offered by its patents and patent applications may be challenged, invalidated or circumvented by its competitors, or Amgen may fail to prevail in present and future intellectual property litigation. Amgen performs a substantial amount of its commercial manufacturing activities at a few key facilities, including in Puerto Rico, and also depends on third parties for a portion of its manufacturing activities, and limits on supply may constrain sales of certain of its current products and product candidate development. An outbreak of disease or similar public health threat, such as COVID-19, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for Amgen’s manufacturing activities, the distribution of Amgen’s products, the commercialization of Amgen’s product candidates, and Amgen’s clinical trial operations, and any such events may have a material adverse effect on Amgen’s product development, product sales, business and results of operations. Amgen relies on collaborations with third parties for the development of some of its product candidates and for the commercialization and sales of some of its commercial products. In addition, Amgen competes with other companies with respect to many of its marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, some raw materials, medical devices and component parts for Amgen’s products are supplied by sole third-party suppliers. Certain of Amgen’s distributors, customers and payers have substantial purchasing leverage in their dealings with Amgen. The discovery of significant problems with a product similar to one of Amgen’s products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on its business and results of operations. Amgen’s efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology Amgen has acquired, may not be successful. A breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability of Amgen’s systems and Amgen’s data. Amgen’s stock price may be volatile and may be affected by a number of events. Amgen’s business performance could affect or limit the ability of the Amgen Board of Directors to declare a dividend or its ability to pay a dividend or repurchase its common stock. Amgen may not be able to access the capital and credit markets on terms that are favorable to it, or at all.
CONTACT: Amgen, Thousand Oaks
Megan Fox, 805-447-1423 (media)
Trish Rowland, 805-447-5631 (media)
CONTACT: International Osteoporosis Foundation
Laura Misteli, Communications Editor, T +41 (0)78 857-1777, email@example.com
CONTACT: NDORMS, University of Oxford
Josie Eade, Communications Officer, T +44 1865 225136, firstname.lastname@example.org
Scott Fleming, Bone Communications, UCB, T +44 7702777378, email@example.com